Similarly, it was shown that erlotinib-resistant NSCLC cells expressed more NEDD4, and NEDD4 promoted erlotinib resistance in NSCLC cells by targeting PTEN degradation [57]. Here, NEDD4 is linked to non-small cell lung carcinoma.